Inhaler Corticosteroid Device Market Gains Momentum Through Integration of AI and Mobile Health Platforms

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Inhaler Corticosteroid Device Market- (By Steroid Types (Beclomethasone Dipropionate, Budesonide, Fluticasone Inhaler Powder, & Mometasone), By Application (Asthma, COPD (Chronic Obstructive Pulmonary Disease) and Others) By End-user (Hospitals and Clinics, Academic and Research Institutes and Respiratory Care Center)) Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Inhaler Corticosteroid Device Market is valued at US$ 616.09 Mn in 2023, and it is expected to reach US$ 886.4 Mn by 2031, with a CAGR of 4.6% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2441

Inhaled corticosteroids (ICS) are widely recognized as a primary therapeutic intervention for managing asthma. With rising levels of air pollution and an increasing incidence of asthma and related respiratory conditions, numerous companies are actively engaged in the development of advanced inhaled corticosteroid delivery devices. This trend is a key driver of growth in the inhaled corticosteroid device market.

The inhaled corticosteroid device market encompasses medical devices specifically designed to deliver corticosteroids directly to the lungs, offering targeted and effective treatment for chronic respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). These devices are essential for long-term disease management and are available in several forms, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. They are commonly used by patients requiring consistent, daily maintenance therapy.

Market expansion is further supported by several macroeconomic and demographic trends, including a growing elderly population, heightened awareness of pulmonary diseases, and increasing global healthcare expenditures. Additionally, the escalation of air pollution worldwide is significantly contributing to the rising demand for inhaled corticosteroid devices, as more individuals seek effective treatments for respiratory health management.

List of Prominent Players in the Inhaler Corticosteroid Device Market:
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Boehringer Ingelheim International GmbH.
• AstraZeneca
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• Amgen Inc.
• Aurobindo Pharma
• Eli Lilly and Company
• Cipla Inc.
• Sumitomo Corporation

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The increasing global prevalence of asthma is a key factor propelling the growth of the inhaled corticosteroids (ICS) market. Asthma, a chronic respiratory disorder that affects various sections of the airway system, leads to inflammation and obstruction of the respiratory tract. Inhaled corticosteroid devices, particularly due to their ease of use, are increasingly preferred by both pediatric and geriatric populations. These devices are widely recognized as a primary treatment option for managing asthma symptoms. Additionally, rising healthcare expenditure is contributing to improved healthcare infrastructure, thereby facilitating greater access to ICS therapies. Public and private sector initiatives aimed at raising awareness about respiratory health, alongside higher disposable incomes and increased smoking prevalence, are further stimulating market growth.

Challenges:
However, several factors are restraining market expansion. The expiration of patents for key branded drugs and the subsequent introduction of cost-effective generic alternatives are expected to limit revenue growth. Inadequate healthcare infrastructure in developing regions, coupled with the relatively high cost of inhaled corticosteroid therapies, poses further challenges. Moreover, potential adverse effects associated with ICS usage-such as oral thrush, coughing, hoarseness, and throat irritation-may discourage patient adherence and impact market adoption. Additionally, the increasing emphasis on cost-effectiveness in healthcare systems influences procurement decisions by healthcare providers and payers. Environmental sustainability is also becoming a critical consideration, with manufacturers increasingly focusing on developing inhalation devices using eco-friendly materials and low-impact propellants.

Regional Trends:
North America holds a dominant position in the inhaled corticosteroid device market, primarily due to its advanced healthcare infrastructure, high prevalence of chronic respiratory conditions, and strong focus on technological innovation. The region's leadership is further supported by an extensive patient base requiring continuous respiratory therapy, as well as a favorable regulatory and reimbursement environment. Ongoing research and development initiatives, strategic partnerships between key industry players and academic institutions, and sustained investment in respiratory healthcare solutions continue to bolster the growth of the ICS device market in North America.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2441

Recent Developments:
• In September 2020, GlaxoSmithKline plc and Innoviva, Inc. announced the U.S. Food and Drug Administration (FDA) approval for a new indication of Trelegy Ellipta. It is also used to treat patients suffering from chronic obstructive pulmonary disease (COPD).
• BreatheSuite is a 2018 startup firm based in St.Johns, Canada. It has developed an integrated inhaler device for medication adherence to manage COPD and asthma.
• CareTRx is a mobile app and sensor offered by Gecko Health for the management of asthma. The device is added to pre-existing inhalers. It aims at assisting patients to better manage their asthma by tracking medication use.

Segmentation of Global Inhaler Corticosteroid Device Market-
Global Inhaler Corticosteroid Device Market- By Steroid Types
• Beclomethasone Dipropionate
• Budesonide
• Fluticasone Inhaler Powder
• Mometasone
Global Inhaler Corticosteroid Device Market- By Application
• Asthma
• COPD (Chronic Obstructive Pulmonary Disease)
• Others
Global Inhaler Corticosteroid Device Market- By End-User
• Hospitals and Clinics
• Academic and Research Institutes
• Respiratory Care Center
Global Inhaler Corticosteroid Device Market- By Region
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/inhaler-corticosteroid-device-market/2441

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.